metamizol sodium, Pytofenon, Fenpyverynyya bromide | Spazgan ampoules, 5 ml, 5 pcs.

Latin name

Spasgan



release solution injection

Packing

5 ampoules of 5 ml.

Pharmacological action

Spazgan - a combined analgesic and antispasmodic, contains three active substances: metamizole sodium - an analgesic non-narcotic drug, pitophenone hydrochloride has papaverine-like action and fenpiverine bromide - M-anticholinergic action.

Has a fast onset, prolonged analgesic and antispasmodic effect.

Indications

Mild or moderate pain with spasms of smooth muscles of the internal organs:

renal colic,

biliary colic,

algodismenorrhea,

intestinal colic

biliary dyskinesia

headache (due to vasospasm).

Contraindications

hypersensitivity to pyrazolone derivatives (butadione, tribuzon), other components of the

preparation severe liver or kidney dysfunctions

genetic lack of glucose-6-phosphate dehydrogenase

tachyarrhythmia

angle-closure form of glaucoma

prostate hypertrophy with a tendency to urinary retention

gastrointestinal disease age under 5 years.

Use during pregnancy and lactation

Contraindicated in pregnancy (especially the first trimester and the last 6 weeks), as well as during lactation.

Composition

1 ampoule (5 ml) contains metamizole sodium 2.5 g,

pitophenone hydrochloride 10 mg,

fenpiverinium bromide 100 mcg

Side effects

allergic reactions (skin rash, pruritus, urticaria, Quincke's edema rarely - anaphylactic shock in very rare cases - malignant exudative erythema (Stevens-Johnson syndrome),

toxic epidermal necrolysis (sredlkel redlle syndrome (usually Lyrell syndrome. long-term use or administration of high doses)

agranulocytosis,

leukopenia,

thrombocytopenia,

impaired renal function: oliguria, anuria, proteinuria, interstitial nephritis,

bronchospasm,

decrease in blood pressure,

gastralgia,

staining of urine in red.

Very rarely - anticholinergic effects (dry mouth, decreased sweating, paresis of accommodation, tachycardia, urinary retention).

Drug Interaction

Concomitant administration of Spazgan with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

Tricyclic antidepressants, contraceptives, allopurinol disrupt metabolic metabolism in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes attenuate the effect of metamizole.

Co-administration with ciclosporin reduces blood levels of the latter.

Sedatives and tranquilizers enhance Spazgan's analgesic action.

Consult your doctor when using these and other medicines at the same time.

Overdose

The following symptoms can be observed with overdosage: vomiting, dry mouth, change in sweating, impaired accommodation, decreased blood pressure, drowsiness, confusion, impaired liver and kidney function, convulsions.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 РC.

Expiration

3 years.

Deystvuyuschee substances

metamizol sodium, Pytofenon, Fenpyverynyya bromide

Vokhard Europe Ltd., India